The Effect of Liraglutide on Renal Function: A Randomized Clinical Trial

This randomized controlled crossover study examined the effect of liraglutide on 24-h urinary albumin excretion rate (UAER) among patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. After placebo treatment, geometric mean (IQR) UAER was 199 (81-531) mg/24-h, mean measured GFR (mGFR) was 75 mL/min/1.73 m2, 24-h systolic blood pressure (SBP) was 145/80 mm Hg, and A1C was 7.7%. Over 12 weeks, use of liraglutide reduced UAER by 32 mg/24-h compared with placebo ([95% CI: 7; 50]; P=0.017). In addition, liraglutide reduced HbA1c by 2.9% (8 mmol/mol; [95% CI: 5; 11]; P<0 .001), weight by 1.8 kg ([95% CI: 0.2; 3.4]; P=0.032), mGFR by 5 mL/min/1.73 m2 ([95% CI: −11; 2]; P=0 .15), and 24-h SBP by 5 mm Hg ([95% CI: −10; 0]; P=0 .07) compared to placebo. Multivariate regression models showed that change in UAER was associated with change in 24-h SBP (P=0 .025) but not with changes in A1C, weight, or mGFR (P≥0.14). Click here for full article